Which has higher earnings & valuation, AGMB or PEPG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is AGMB or PEPG more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A PepGen N/A -59.89% -49.62%

Which has stronger earnings & valuation, ZURA or PEPG?

Zura Bio is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.09 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is ZURA or PEPG more profitable?

Zura Bio's return on equity of -55.74% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -55.74% -48.07% PepGen N/A -59.89% -49.62%

Does the media prefer ZURA or PEPG?

In the previous week, PepGen had 1 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for PepGen and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.87 beat PepGen's score of 0.51 indicating that Zura Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is PEPG or IPSC more profitable?

Century Therapeutics' return on equity of -49.89% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Century Therapeutics N/A -49.89% -37.42%

Does the media favor PEPG or IPSC?

In the previous week, PepGen had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 3 mentions for PepGen and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.96 beat PepGen's score of 0.51 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Century Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PEPG or LYEL?

In the previous week, Lyell Immunopharma had 1 more articles in the media than PepGen. MarketBeat recorded 4 mentions for Lyell Immunopharma and 3 mentions for PepGen. PepGen's average media sentiment score of 0.51 beat Lyell Immunopharma's score of 0.38 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ENTA or PEPG?

In the previous week, PepGen had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for PepGen and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.76 beat PepGen's score of 0.51 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

PepGen (PEPG) Competitors

$1.42 -0.03 (-2.07%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$1.42 +0.01 (+0.35%)

As of 06/3/2026 07:33 PM Eastern

Compare

PEPG vs. AGMB, ZURA, IPSC, LYEL, and ENTA

Should you buy PepGen stock or one of its competitors? MarketBeat compares PepGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PepGen include AgomAb Therapeutics (AGMB), Zura Bio (ZURA), Century Therapeutics (IPSC), Lyell Immunopharma (LYEL), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry.

How does PepGen compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and PepGen (NASDAQ:PEPG) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

58.0% of PepGen shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, PepGen had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for PepGen and 2 mentions for AgomAb Therapeutics. PepGen's average media sentiment score of 0.51 beat AgomAb Therapeutics' score of 0.33 indicating that PepGen is being referred to more favorably in the news media.

Company	Overall Sentiment
AgomAb Therapeutics	Neutral
PepGen	Positive

AgomAb Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 166.67%. PepGen has a consensus price target of $11.60, suggesting a potential upside of 716.90%. Given PepGen's higher possible upside, analysts plainly believe PepGen is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

AgomAb Therapeutics' return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
PepGen	N/A	-59.89%	-49.62%

Summary

PepGen beats AgomAb Therapeutics on 6 of the 9 factors compared between the two stocks.

How does PepGen compare to Zura Bio?

Zura Bio (NASDAQ:ZURA) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Zura Bio has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market. Comparatively, PepGen has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

Zura Bio's return on equity of -55.74% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
PepGen	N/A	-59.89%	-49.62%

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 14.2% of Zura Bio shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zura Bio is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

Zura Bio currently has a consensus price target of $10.75, indicating a potential upside of 178.50%. PepGen has a consensus price target of $11.60, indicating a potential upside of 716.90%. Given PepGen's higher possible upside, analysts plainly believe PepGen is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, PepGen had 1 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for PepGen and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.87 beat PepGen's score of 0.51 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zura Bio beats PepGen on 7 of the 13 factors compared between the two stocks.

How does PepGen compare to Century Therapeutics?

PepGen (NASDAQ:PEPG) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

PepGen currently has a consensus target price of $11.60, suggesting a potential upside of 716.90%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 129.47%. Given PepGen's stronger consensus rating and higher probable upside, equities research analysts clearly believe PepGen is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has higher revenue and earnings than PepGen. Century Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Century Therapeutics	$109.16M	3.42	-$9.58M	-$1.14	N/A

In the previous week, PepGen had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 3 mentions for PepGen and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.96 beat PepGen's score of 0.51 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.0% of PepGen shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PepGen has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

Century Therapeutics' return on equity of -49.89% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Century Therapeutics	N/A	-49.89%	-37.42%

Summary

PepGen and Century Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does PepGen compare to Lyell Immunopharma?

PepGen (NASDAQ:PEPG) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

PepGen has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

In the previous week, Lyell Immunopharma had 1 more articles in the media than PepGen. MarketBeat recorded 4 mentions for Lyell Immunopharma and 3 mentions for PepGen. PepGen's average media sentiment score of 0.51 beat Lyell Immunopharma's score of 0.38 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PepGen has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. PepGen's return on equity of -59.89% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

58.0% of PepGen shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PepGen has higher earnings, but lower revenue than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Lyell Immunopharma	$40K	7,331.45	-$274.45M	-$13.80	N/A

PepGen currently has a consensus price target of $11.60, indicating a potential upside of 716.90%. Lyell Immunopharma has a consensus price target of $43.25, indicating a potential upside of 244.07%. Given PepGen's higher probable upside, equities research analysts plainly believe PepGen is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

PepGen beats Lyell Immunopharma on 10 of the 15 factors compared between the two stocks.

How does PepGen compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Enanta Pharmaceuticals currently has a consensus price target of $20.29, suggesting a potential upside of 80.48%. PepGen has a consensus price target of $11.60, suggesting a potential upside of 716.90%. Given PepGen's higher probable upside, analysts clearly believe PepGen is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Enanta Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, PepGen has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

In the previous week, PepGen had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for PepGen and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.76 beat PepGen's score of 0.51 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Enanta Pharmaceuticals has higher revenue and earnings than PepGen. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.00	-$81.89M	-$2.59	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PepGen has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. PepGen's return on equity of -59.89% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
PepGen	N/A	-59.89%	-49.62%

Summary

Enanta Pharmaceuticals beats PepGen on 8 of the 15 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEPG vs. The Competition

Export

Metric	PepGen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$100.29M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-0.81	17.78	22.17	24.18
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	0.66	6.63	9.84	6.72
Net Income	-$89.65M	$24.20M	$3.57B	$337.19M
7 Day Performance	-5.33%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-5.96%	45.50%	26.49%	33.10%

PepGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEPG PepGen	2.766 of 5 stars	$1.42 -2.1%	$11.60 +716.9%	-7.2%	$100.29M	N/A	N/A	30	Analyst Downgrade
AGMB AgomAb Therapeutics	N/A	$11.50 flat	$32.00 +178.3%	N/A	$416.73M	N/A	N/A	62	Gap Down
ZURA Zura Bio	3.4591 of 5 stars	$4.36 flat	$10.75 +146.6%	+260.7%	$413.68M	N/A	N/A	3	News Coverage
IPSC Century Therapeutics	2.2845 of 5 stars	$2.26 flat	$3.67 +62.2%	+263.1%	$407.60M	$109.16M	N/A	170	Gap Down
LYEL Lyell Immunopharma	2.2606 of 5 stars	$17.46 flat	$43.00 +146.3%	+57.3%	$407.41M	$40K	N/A	270	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PEPG) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PepGen (PEPG) Competitors

PEPG vs. AGMB, ZURA, IPSC, LYEL, and ENTA

How does PepGen compare to AgomAb Therapeutics?

Summary

How does PepGen compare to Zura Bio?

Summary

How does PepGen compare to Century Therapeutics?

Summary

How does PepGen compare to Lyell Immunopharma?

Summary

How does PepGen compare to Enanta Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PepGen (PEPG) Competitors

PEPG vs. AGMB, ZURA, IPSC, LYEL, and ENTA

How does PepGen compare to AgomAb Therapeutics?

Which has higher earnings & valuation, AGMB or PEPG?

Do institutionals & insiders have more ownership in AGMB or PEPG?

Does the media refer more to AGMB or PEPG?

Do analysts prefer AGMB or PEPG?

Is AGMB or PEPG more profitable?

Summary

How does PepGen compare to Zura Bio?

Which has more risk & volatility, ZURA or PEPG?

Is ZURA or PEPG more profitable?

Do institutionals and insiders believe in ZURA or PEPG?

Which has stronger earnings & valuation, ZURA or PEPG?

Do analysts prefer ZURA or PEPG?

Does the media prefer ZURA or PEPG?

Summary

How does PepGen compare to Century Therapeutics?

Do analysts rate PEPG or IPSC?

Which has preferable valuation & earnings, PEPG or IPSC?

Does the media favor PEPG or IPSC?

Do institutionals & insiders hold more shares of PEPG or IPSC?

Which has more volatility & risk, PEPG or IPSC?

Is PEPG or IPSC more profitable?

Summary

How does PepGen compare to Lyell Immunopharma?

Which has more volatility & risk, PEPG or LYEL?

Does the media favor PEPG or LYEL?

Is PEPG or LYEL more profitable?

Do insiders and institutionals believe in PEPG or LYEL?

Which has stronger valuation and earnings, PEPG or LYEL?

Do analysts prefer PEPG or LYEL?

Summary

How does PepGen compare to Enanta Pharmaceuticals?

Do analysts rate ENTA or PEPG?

Which has more volatility & risk, ENTA or PEPG?

Does the media refer more to ENTA or PEPG?

Which has preferable valuation & earnings, ENTA or PEPG?

Do insiders & institutionals hold more shares of ENTA or PEPG?

Is ENTA or PEPG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools